Status:
WITHDRAWN
Contrast-Enhanced Ultrasound in Diagnosing Patients With Liver Cancer Undergoing Yttrium-90 Radioembolization
Lead Sponsor:
University of Southern California
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This pilot clinical trial studies how well contrast-enhanced ultrasound in diagnosing patients with liver cancer who are undergoing Yttrium-90 radioembolization. Contrast-enhanced ultrasound may provi...
Detailed Description
PRIMARY OBJECTIVES: I. Investigate the relationship between hepatocellular carcinoma (HCC) tumor perfusion on pre-procedural contrast-enhanced ultrasound (CEUS) time intensity curve (TIC) and post-pr...
Eligibility Criteria
Inclusion
- Patients scheduled for 90Y radioembolization for HCC as part of their standard of care
Exclusion
- Patients who have already received tumor treatment (either systemic or loco-regional such as previous Y90RE, microwave or radiofrequency \[RF\] ablation or transarterial chemoembolization \[TACE\])
- Pregnant or nursing
- Known cardiac shunt
- Known pulmonary hypertension
- History of hypersensitivity to Definity (perflutren lipid microsphere) or Lumason
- History of hypersensitivity to iodinated contrast agent
- Cannot consent for himself or herself
Key Trial Info
Start Date :
November 7 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 7 2020
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03300401
Start Date
November 7 2017
End Date
November 7 2020
Last Update
May 16 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
USC/Norris Comprehensive Cancer Center
Los Angeles, California, United States, 90033